Tranexamic Acid Tablet
Product Images NDC 50268-772

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tranexamic Acid (NDC 50268-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (772 13)

Packaging label for Tranexamic Acid USP Tablets, 650 mg oral tablets. The label indicates the product is prescription only with 30 tablets (three blister strips of 10 each) per unit dose package. Manufactured by AvPAK with storage instructions and usual adult dosage guidelines included on the label.*

FDA Label Image

4 (Table 4)

A data table titled 'Mean Reduction from Baseline in Menstrual Blood Loss in Women with Heavy Menstrual Bleeding (Study 1)' compares treatment arms including Tranexamic Acid USP tablets at 3900 mg/day and 1950 mg/day doses versus placebo. It shows the number of subjects, baseline mean menstrual blood loss in mL, least squares mean reduction, and percent reduction. The 3900 mg/day group has the highest reduction at 39%, followed by 25% for 1950 mg/day, and 5% for placebo.*

FDA Label Image

5 (Table 5)

A data table titled 'Secondary Outcomes in 3-Cycle Study in Women with Heavy Menstrual Bleeding (Study 1)'. It presents results comparing 3900 mg/day tranexamic acid USP tablets versus placebo on outcomes including Social and Leisure Activities, Physical Activities, and Reduction in Large Stains. The table shows sample sizes, baseline means, least squares mean reductions, and responder percentages. Footnotes explain response categories, significance, and definitions of responders.*

FDA Label Image

Chemical Structure (Tranexamic 01)

Chemical structure diagram of Tranexamic Acid, showing a cyclohexane ring with attached amino and carboxyl functional groups.*

FDA Label Image

Figure 1 (Tranexamic 02)

Line graph comparing mean menstrual blood loss (mL) over a treatment period for Tranexamic Acid 3900 mg/day and placebo in both 3-cycle and 6-cycle studies. The x-axis shows treatment periods from baseline through six cycles, and the y-axis shows mean menstrual blood loss in milliliters. The graph displays decreases in blood loss after treatment begins, with distinct lines for each study group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.